Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei ET-66 metabolites
- Development stage
- Preclinical
- Lead developer
- Jinqi Biological Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Lactobacillus paracasei ET-66 metabolites, commonly marketed under the brand name ADP-1, are postbiotic preparations derived from the heat-inactivation of the *Lactobacillus paracasei* strain ET-66. Developed by Synbio Tech, these metabolites are primarily utilized as functional ingredients in oral care products such as lozenges, toothpaste, and mouthwashes. The primary therapeutic mechanism is the specific co-aggregation with *Streptococcus mutans*, the major pathogen responsible for dental caries; this physical binding prevents the pathogen from adhering to dental surfaces and facilitates its clearance from the oral cavity. Additionally, ET-66 metabolites interact with host immune receptors, including Toll-like receptors, to modulate inflammatory responses and support mucosal immunity. The product is widely available as a dietary supplement and food ingredient for the prevention of dental caries and the maintenance of oral hygiene.
- Brand names
- ADP-1ADP1ADP 1
- Other names
- heat-killed Lactobacillus paracasei ET-66ET-66 postbioticsET66 postbioticsET 66 postbioticsLactobacillus paracasei ET-66 metabolites
Beyond the preview
Go deeper on lactobacillus paracasei ET-66 metabolites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei ET-66 metabolites.